Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8018411rdf:typepubmed:Citationlld:pubmed
pubmed-article:8018411lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:8018411lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8018411lifeskim:mentionsumls-concept:C0038880lld:lifeskim
pubmed-article:8018411lifeskim:mentionsumls-concept:C1319315lld:lifeskim
pubmed-article:8018411lifeskim:mentionsumls-concept:C1510779lld:lifeskim
pubmed-article:8018411lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:8018411lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:8018411lifeskim:mentionsumls-concept:C0681828lld:lifeskim
pubmed-article:8018411pubmed:issue4lld:pubmed
pubmed-article:8018411pubmed:dateCreated1994-8-4lld:pubmed
pubmed-article:8018411pubmed:abstractTextSuramin, a polysulphonated naphthylurea proven to be an effective anticancer agent against selected tumours, and alpha 2A-interferon (alpha 2A-IFN) were investigated for their combined effects on HCT-8, HCT-15, CL-D, SW-480 and SW-620 human colorectal adenocarcinoma cell lines. All lines were sensitive to clinically achievable concentrations of suramin in a dose-dependent manner, while alpha 2A-IFN alone induced only a modest reduction of cell growth. Concomitant treatment with suramin and alpha 2A-IFN resulted in a synergistic inhibition of cell viability in each cell line at all doses tested. However, when suramin and alpha 2A-IFN were administered sequentially, inhibition of cell viability was clearly dependent on the timing of treatment schedule, with maximum effect obtained when alpha 2A-IFN was administered prior to suramin. In contrast, pretreatment with suramin was markedly inferior to the former one. In conclusion, suramin and alpha 2A-IFN exert a synergistic effect on human colorectal cell proliferation in vitro at clinically achievable concentrations. This observation may have clinical relevance although the mechanisms of interaction remain to be elucidated.lld:pubmed
pubmed-article:8018411pubmed:languageenglld:pubmed
pubmed-article:8018411pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8018411pubmed:citationSubsetIMlld:pubmed
pubmed-article:8018411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8018411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8018411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8018411pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8018411pubmed:statusMEDLINElld:pubmed
pubmed-article:8018411pubmed:issn0959-8049lld:pubmed
pubmed-article:8018411pubmed:authorpubmed-author:Del TaccaMMlld:pubmed
pubmed-article:8018411pubmed:authorpubmed-author:MalvaldiGGlld:pubmed
pubmed-article:8018411pubmed:authorpubmed-author:YonemitsuHHlld:pubmed
pubmed-article:8018411pubmed:authorpubmed-author:ZaccariJJlld:pubmed
pubmed-article:8018411pubmed:authorpubmed-author:FalconeAAlld:pubmed
pubmed-article:8018411pubmed:authorpubmed-author:DanesiRRlld:pubmed
pubmed-article:8018411pubmed:authorpubmed-author:PieracciDDlld:pubmed
pubmed-article:8018411pubmed:authorpubmed-author:CianciCClld:pubmed
pubmed-article:8018411pubmed:authorpubmed-author:PfannerEElld:pubmed
pubmed-article:8018411pubmed:authorpubmed-author:AndreuccettiM...lld:pubmed
pubmed-article:8018411pubmed:issnTypePrintlld:pubmed
pubmed-article:8018411pubmed:volume30Alld:pubmed
pubmed-article:8018411pubmed:ownerNLMlld:pubmed
pubmed-article:8018411pubmed:authorsCompleteYlld:pubmed
pubmed-article:8018411pubmed:pagination516-20lld:pubmed
pubmed-article:8018411pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:meshHeadingpubmed-meshheading:8018411-...lld:pubmed
pubmed-article:8018411pubmed:year1994lld:pubmed
pubmed-article:8018411pubmed:articleTitleSynergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies.lld:pubmed
pubmed-article:8018411pubmed:affiliationDivisione Oncologia Medica, Ospedale S. Chiara, Pisa, Italy.lld:pubmed
pubmed-article:8018411pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8018411pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed